cooper slightli underwhelm bright prospect
come focu product
page full analyst note may
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research may
estim
price data aug
rate updat aug
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
cash-pay busi sticki custom competitor
contact len industri attract market opinion
valeant control approxim global market
industri regul creat strong barrier entri keep new
entrant away remain pure-play contact len
manufactur fell behind peer earli
competitor brought silicon hydrogel lens market
launch full portfolio lens regain lost
share larg detriment novarti alcon busi
think long-term outlook rel healthi even
though concern increas competit
specialti len market benefit higher-pr product
offer silicon hydrogel one-day premium lens
expect expand margin maintain double-digit
believ len sale growth driven two key
factor first see increas adopt contact lens
world-wide larg emerg market unpreced rise
myopia particularli under-penetrated asian market
present long-term growth opportun histor adopt
rate second believ exist custom trade
premium product daili dispos lens grow
popular across globe daili lens conveni
custom reduc risk infect silicon hydrogel lens
provid comfort len wearer compar tradit
well-posit benefit key driver
consid moatworthi busi
surgic segment contribut one fourth total revenu
acquisit paragard nonhormon copper iud
expect continu invest surgic segment
increas sale effort paragard well tuck-in
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
cooper compani oper two unit coopervis coopersurg
account total sale coopervis one world
top four develop manufactur contact lens
coopervis sale intern territori second unit
coopersurg develop manufactur diagnost surgic
product gynecologist obstetrician includ paragard iud
acquir teva
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
bright
prospect come focu product
cooper compani report second-quart revenu
million increas year year slightli
estim heighten market spend around
paragard mysight larg led decreas pro forma
oper margin fair valu estim
remain unchang maintain posit
possess narrow moat vision segment
due strong brand loyalti foster key account
relationship cost advantag manufactur
sale vision segment increas line
expect year year echo last quarter
coopervis propel strong perform
daili silicon hydrogel lens clariti myday
softer-than-expect quarter
growth howev histor revenu increas
back half year therefor expect coopervis
abl attain growth averag reach
revis fiscal guidanc estim nearli billion
optimist new myopia manag
product misight continu see increas adopt
larg yet uncertain potenti
depend approv
food drug
step overal busi surgic divis
grew revenu year year slightli
expect keep persist trend last
drove growth remain optimist
paragard potenti manag invest heavili
market expect overal iud market
continu grow fertil segment perform
poorli bog overal surgic segment
revenu declin reinforc view competitor
advantag fertil space
maintain fair valu estim per
multipl
expect on-going adopt silicon
hydrogel product combin custom upgrad
daili dispos lens drive firm five-year
compound annual growth rate expect market
share gain margin expans continu consum
upgrad newer lens biofin energi
control frequent replac space
daili contact len space forecast modest
market share gain consum base move
higher-margin lens believ margin expans
drive even faster earn growth manufactur yield
improv custom continu switch higher-pr
manufactur effici contact lens expand
oper margin
aim second-largest len compani
market share world-wide next two year
believ track achiev goal current
underindex asia nearli two third sale
region stem japan alon expect
build market share high adopt rate region
continu weigh threat competitor
johnson johnson aggress
move toric multifoc space recent year
addit paragard cooper surgic portfolio
expect segment contribut mid-single-digit growth
boost overal gross margin near term expect
alloc oper expens new sale
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
bear case assum sale growth slow
five-year compound-annual-growth-rate oper margin
result fair valu estim could occur
stumbl incorpor anoth acquisit
face greater-than-expect declin surgic
lens-car busi due competit pressur
believ central player oligopolist
contact len industri narrow moat due intang
asset cost advantag scale hold
roughli share global contact len market
surpass novarti alcon johnson
johnson along valeant bausch lomb
compani make global contact len
market coopervis shield barrier entri
vision-car market allow firm produc consist
econom profit expect materi chang
contact len adopt overal given inconveni
eyeglass complic expens associ
coopervis contribut overal sale
fiscal leader multifoc toric contact
lens specialti lens
compani sale requir complex manufactur
fit process sold premium price spheric
lens johnson johnson came toric
daili silicon hydrogel lens
contact len maker offer toric multifoc varieti
daili dispos silicon hydrogel lens allow
gain modest share specialti len space make
late entri silicon hydrogel gain
share past sever year silicon hydrogel lens
prolifer thank broad portfolio spheric
toric multifoc lens across three modal
face addit upsid contact len wearer upgrad
lens
initi continu research develop
surgic segment believ taper
cash-pay natur contact len market support
medium uncertainti rate
bullish scenario assum greater proport
sale firm myday clariti daili contact lens
market share gain len segment steadi growth
surgic segment increas five-year compound-annual-growth-rate
base case scenario
assum oper margin expand daili
lens carri high gross profit dollar term compar
modal margin seem like improv
growth rate daili silicon hydrogel lens higher
expect case strength paragard
rest surgic busi accret gross margin
start contribut larger proport sale
assumpt arriv fair valu estim
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
regul natur contact len industri fortifi
coopervis competit posit intang
asset first lens must approv regul
 food drug administr typic
patent protect exampl coopervis one
mani patent aquaform technolog techniqu use
biofin monthli avaira biweekli famili
aquaform high oxygen transmiss low
modulu keep len softer flexibl
competitor second research develop
spend allow firm invest new technolog
bring new lens market third current law
patient must visit licens optometrist purchas
contact lens must get prescript fill everi time
need order new suppli prescript
brand-specif requir new entrant build
level trust medic commun doctor
hesit embrac new product
proven record safeti often receiv rebat
manufactur necessari doctor visit lead doctor
recommend establish brand bolster
coopervis competit posit contact len
addit custom content certain brand
lens unlik switch manufactur
custom comfort product unlik
chang lens minor improv small reduct
price contact lens typic come
suppli discourag frequent brand-switch
relationship
manufactur like chang brand len
prescrib given custom contact lens
larg paid pocket coopervis larg
unaffect pressur insur seen ration
price prevail past decad expect
typic strong
price war emerg
moreov manufactur contact lens capital-intens
complic process creat cost advantag
top four len manufactur cooper manufactur
knowledg continu expand evidenc improv
gross margin better factori util new entrant
would need invest signific time fix cost
suffici qualiti meet regulatori requir new
product typic sold loss first coupl
year manufactur reach necessari scale bring
cost per unit due sticki custom base
space new competitor would unlik win
enough new patient ever reach critic mass need
oper profit given up-front cost
difficulti captur new custom exist brand
anticip new entrant space
believ coopersurg overal sale
fiscal produc medic devic relat
women health contribut econom moat
due numer establish competitor johnson
 johnson coopersurg growth
larg driven heavi activ includ
firm recent billion acquisit teva paragard
iud although manag expand segment
portfolio recent year yet view
moatworthi busi think coopersurg
coopervis benefit cost synergi given
award stabl moat trend sinc launch
silicon hydrogel len portfolio maintain
gain market share categori lens still
expect materi chang competit dynam
among
manufactur also think barrier entri
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
substanti enough preclud new competitor
enter market custom unlik switch
brand contact lens expand portfolio
len modal specialti lens help gain
market share rel alcon bausch lomb novarti
recent express interest spin alcon
busi valeant balloon debt
uncertainti ophthalmolog segment bausch
lomb develop bode well coopervis
control lion share industri give firm
price power peer
think coopersurg competit posit
materi chang either although firm invest
widen surgic segment ivf fertil portfolio
competit women health among devic maker
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
ocoopervis benefit custom trade
weekli monthli contact lens expens
oa signific portion revenu come
foreign currenc leav compani suscept
chang exchang rate
ocontinu trade-up trend silicon hydrogel
drive growth firm len busi
oparagard nonhormon iud approv
 seriou competit
ocoop competitor larger divers
revenu stream allow greater research
laggard bring silicon hydrogel
lens market indic
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
believ solid financi strength
compani took billion debt fiscal acquir
teva paragard iud vision surgic segment
gener enough cash allow compani
pay debt continu invest busi
histor troubl pay debt
debt/ebitda fiscal end
fiscal firm complet debt
time ebitda even addit leverag
anticip challeng meet
oblig given sticki custom minim econom
sensit contact len market alreadi extrem
consolid especi sauflon acquisit
futur larg acquisit seem unlik coopervis
firm may seek addit capit pursu bolt-on
deal surgic divis coopersurg acquir
compani sinc project
cash-pay natur contact len market support
medium uncertainti rate cooper histor
innov leader firm late
game silicon hydrogel product risk
behind curv futur innov howev
briskli regain market share later come
one complet suit silicon hydrogel
product capit weak alcon
bausch lomb opinion abil quickli
regain lost ground highlight stabil industri
issu recal avaira line lens
minor issu recal appear caus
sustain damag firm brand seriou
recal potenti damag reput
ultim reduc earn final signific portion
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
revenu come foreign currenc leav cooper
expos chang foreign exchang rage also
indic impact hurrican maria septemb
compani expos risk associ
natur disast primari facil locat
unit kingdom puerto rico hungari costa rica
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
repres date owner name posit common share held report holder issuer
new york mellon corp
share
fund
share
fund
manag behind innov curv vision
care invest enough develop silicon
hydrogel lens howev coopervis sinc regain
lost ground quickli adapt market trend
focus specialti lens addit believ
manag kept sound merger acquisit
polici segment opinion done
commend job recent year build portfolio
product expand global market share
histor manag larg use excess capit
bolt-on acquisit except
acquisit sauflon billion recent
billion acquisit paragard believ benefit
sauflon deal outweigh associ expens
oper difficulti firm face year
follow acquisit firm use acquisit
support moat vision care enter
mass-market hydrogel space financ paragard
acquisit ad billion debt balanc
sheet also ad steadi high-margin busi
expand surgic divis product portfolio
believ manag respons run two
dispar segment coopervis coopersurg
alloc cash flow new opportun come
industri acquisit paragard iud
exampl strategi
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
coopersurg first-quart revenu increas pro
forma year year driven increas paragard
led improv growth franchis
skeptic spend translat materi impact
long-term project due competit
similar product women health market howev
effect capit market effort
increas market share iud market especi
 paragard nonhormon iud
option could increas revenu outlook potenti
rais fair valu estim
cooper see strong perform fuel surgic
may slightli increas fair valu estim respons
outpac revenu growth surgic busi
segment versu project increas
ep outlook per share
per share howev revis larg attribut
abnorm low effect tax rate
quarter due favor intern restructur
audit settlement unit kingdom
anticip tax rate increas back
midteen though increas revenu
million versu annual estim
quarter oper margin dip basi point
primarili attribut invest sell
market vision surgic segment
maintain posit possess narrow moat
vision segment due strong brand loyalti foster
key account relationship cost advantag
manufactur switch cost due consum
coopervis year-over-year growth quarter
match expect coopervis continu
outpac soft contact len market growth thank larg
growth daili lens progress
roughli tie novarti alcon second-plac market
share expect sustain level growth
thank market on-going shift toward daili lens
increas incid myopia cooper grow
presenc asia compani underindex
versu peer within daili use modal cooper
myday premium offer continu grow
perform well howev rapid growth daili silicon
put pressur vision segment margin
expect increas product capac
respons sale improv improv
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
financi summari forecast
fiscal year end octob
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
fiscal year end octob
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
